Thematic Exposure -- 7/10
Merck is a concentrated, franchise-led pharma whose thematic exposure runs through a handful of
mega-products. The single most important is Keytruda (PD-1 immuno-oncology), ~49% of total company
revenue. Merck holds genuinely dominant share in its two most important themes -- PD-1/PD-L1 oncology
(~49%, #1) and HPV vaccines (~71-73%, near-monopoly) -- which clears the oligopoly hard gate, so the
5/10 fragmentation ceiling does NOT apply. Winrevair adds a fresh first-in-class PAH monopoly.
Held out of 9-10 by theme durability, not dominance: the crown-jewel Keytruda IV faces the largest
patent cliff in pharma (2028-2029).
Weight: 35%
Keytruda -- Dominant #1 in PD-1/PD-L1 Oncology
Oligopoly Theme -- Dominant, Durable, On a Clock
Keytruda holds ~49% of the PD-1/PD-L1 inhibitor market (#1; Opdivo #2 ~26%) with 40+ FDA-approved
indications and is ~49% of company revenue. The moat is indication breadth, trial data, and
standard-of-care entrenchment -- a hospital cannot "replace" Keytruda inside 12 months because it
IS the backbone of care across lung, melanoma, and many tumors. The share is durable; but the U.S.
IV patent expires 2028-2029 (EU 2030-31), so the revenue is on a clock. Subcutaneous Keytruda
(Qlex) is the explicit mitigation. Keytruda +7% ex-FX FY25.
Gardasil -- Near-Monopoly in HPV Vaccines
Structural Near-Monopoly -- But Theme Going Backwards on China
Gardasil is ~71-73% of global HPV vaccine revenue (GSK Cervarix ~12-14%) -- the only 9-valent
option in most markets. The moat is regulatory/clinical (decade-plus efficacy data) and
manufacturing scale; buyers are governments and public-health programs. Sticky, but exposed to
single-country policy: the China headwind drove -39% ex-FX in FY25. HPV vaccine TAM ~$6.8B growing
to ~$13.2B by 2034 (~7.7% CAGR).
Winrevair -- New First-in-Class PAH Monopoly
Fastest-Growing Asset -- No In-Class Competitor
Winrevair is the first-and-only activin-signaling inhibitor for PAH -- effectively 100% of its
sub-class -- expanded by the ZENITH outcomes data (Oct-25 label). No direct in-class competitor
today; replaceable only by a future in-class entrant, none imminent. The fastest-growing asset in
the portfolio at +87% ex-FX in 1Q26. PAH market ~$7-8B.
Animal Health -- NOT a Leadership Theme
Follower in a Fragmented Market
Animal Health (~10% of revenue) is #2-3 behind Zoetis (~21%), in a broad market where the top-5
control only ~40%. A quality business but a follower in a fragmented market -- it does not carry
the thematic case. MRK Animal Health +9% ex-FX FY25.
Segment / Franchise Table (FY2025, Global)
| Franchise / Theme | % of Rev | Market Share | Theme Growth |
|---|---|---|---|
| Keytruda (PD-1/PD-L1) | 48.7% | ~49% (#1; Opdivo #2 ~26%) | IO ~$45-50B+; Keytruda +7% ex-FX FY25 |
| Gardasil (HPV) | 8.0% | ~71-73% (near-monopoly) | ~7.7% CAGR; but -39% ex-FX FY25 (China) |
| Winrevair (PAH) | 2.2% | First-in-class; ~100% of sub-class | Fastest-growing: +87% ex-FX 1Q26 |
| Other Pharmaceutical | ~30.5% | Mixed (Januvia declining, launches) | Mixed; offsets Keytruda concentration |
| Animal Health | 9.8% | ~10-12% (#2-3; Zoetis #1 ~21%) | Low-single-digit; +9% ex-FX FY25 |
| Total Company | 100% | — | +2% ex-FX FY25; +3% ex-FX 1Q26 |
Oligopoly Gate
| Criterion | Result |
|---|---|
| Keytruda share of PD-1/PD-L1 | ~49% (#1) |
| Any segment >30% share? | Yes (Keytruda ~49%, Gardasil ~72%) |
| Top-2 control >70% of a market? | Yes (PD-1/PD-L1 top-2 ~75%) |
| Price-setter or price-taker? | Price-setter (branded, patent-protected) |
| Gate result | PASS |
7/10 — Merck clears the oligopoly gate
decisively: Keytruda is the #1 PD-1/PD-L1 asset (~49% share inside a top-2-controls-75% oligopoly),
Gardasil is a near-monopoly in HPV (~71-73%), and Winrevair adds a fresh first-in-class PAH monopoly
compounding fast (+87% ex-FX 1Q26). Positions are durable on clinical/regulatory moats and Merck is a
price-setter. What keeps this out of 9-10 is theme durability, not dominance: the crown-jewel Keytruda
IV faces the largest patent cliff in pharma (2028-2029), Gardasil's theme is going backwards on China
(-39% ex-FX FY25), and total company growth is only +2-3% ex-FX -- below the >10% theme-growth bar.
Reconciling dominant share vs sub-GDP company growth.
The franchises dominate growing themes, yet company-level growth (+2-3% ex-FX) sits below GDP.
The 7 (not a 5) holds because the score rewards segment-level dominance in growing themes plus the
Winrevair/launch optionality diversifying the base -- not the blended, cliff-suppressed company
average.
Data sourced from Daloopa.